Month: November 2022

Development of a robotics platform for automated multi-ionization mass spectrometry was written by Karki, Santosh;Meher, Anil K.;Inutan, Ellen D.;Pophristic, Milan;Marshall, Darrell D.;Rackers, Kevin;Trimpin, Sarah;McEwen, Charles N.. And the article was included in Rapid Communications in Mass Spectrometry in 2021.Safety of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid The following contents are mentioned in the article:

Successful coupling of a multi-ionization automated platform with com. available mass spectrometers provides improved coverage of compounds in complex mixtures through implementation of new and traditional ionization methods. The versatility of the automated platform is demonstrated through coupling with mass spectrometers from two different vendors. Standards and complex biol. samples were acquired using electrospray ionization (ESI), solvent-assisted ionization (SAI) and matrix-assisted ionization (MAI). The MS® prototype automated platform samples from 96- or 384-well plates as well as surfaces. The platform interfaces with Thermo Fisher Scientific mass spectrometers by replacement of the IonMax source, and on Waters mass spectrometers with addnl. minor source inlet modifications. The sample is transferred to the ionization region using a fused-silica or metal capillary which is cleaned between acquisitions using solvents. For ESI and SAI, typically 1μL of sample solution is drawn into the capillary tube and for ESI slowly dispensed near the inlet of the mass spectrometer with voltage placed on the delivering syringe barrel to which the tubing is attached, while for SAI the sample delivery tubing inserts into the inlet without the need for high voltage. For MAI, typically, 0.2μL of matrix solution is drawn into the syringe before drawing 0.1μL of the sample solution and dispensing to dry before insertion into the inlet. A comparison study of a mixture of angiotensin I, verapamil, crystal violet, and atrazine representative of peptides, drugs, dyes, and herbicides using SAI, MAI, and ESI shows large differences in ionization efficiency of the various components. Solutions of a mixture of erythromycin and azithromycin in wells of a 384-microtiter well plate were mass analyzed at the rate of ∼1 min per sample using MAI and ESI. The authors report the anal. of bacterial extracts using automated MAI and ESI methods. Finally, the ability to perform surface anal. with the automated platform is also demonstrated by directly analyzing dyes separated on a thin-layer chromatog. (TLC) plate and compounds extracted from the surface of a beef liver tissue section. The prototype multi-ionization automated platform offers solid matrix introduction used with MAI, as well as solution introduction using either ESI or SAI. The combination of ionization methods extends the types of compounds which are efficiently ionized and is especially valuable with complex mixtures as demonstrated for bacterial extracts While coupling of the automated multi-ionization platform to Thermo and Waters mass spectrometers is demonstrated, it should be possible to interface it with most com. mass spectrometers. This study involved multiple reactions and reactants, such as 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0Safety of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid).

2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. Piperidine has a role as a reagent, a protic solvent, a base, a catalyst, a plant metabolite, a human metabolite and a non-polar solvent. Several piperidine alkaloids isolated from natural herbs, were found to exhibit antiproliferation and antimetastatic effects on various types of cancers both in vitro and in vivo for example Piperine, Evodiamine, Matrine, Berberine and Tetrandine.Safety of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

Target, suspect and non-target screening analysis from wastewater treatment plant effluents to drinking water using collision cross section values as additional identification criterion was written by Hinnenkamp, Vanessa;Balsaa, Peter;Schmidt, Torsten C.. And the article was included in Analytical and Bioanalytical Chemistry in 2022.Computed Properties of C32H39NO4 The following contents are mentioned in the article:

The anthropogenic entry of organic micropollutants into the aquatic environment leads to a potential risk for drinking water resources and the drinking water itself. Therefore, sensitive screening anal. methods are needed to monitor the raw and drinking water quality continuously. Non-target screening anal. has been shown to allow for a more comprehensive investigation of drinking water processes compared to target anal. alone. However, non-target screening is challenging due to the many features that can be detected. Thus, data processing techniques to reduce the high number of features are necessary, and prioritization techniques are important to find the features of interest for identification, as identification of unknown substances is challenging as well. In this study, a drinking water production process, where drinking water is supplied by a water reservoir, was investigated. Since the water reservoir provides surface water, which is anthropogenically influenced by wastewater treatment plant (WWTP) effluents, substances originating from WWTP effluents and reaching the drinking water were investigated, because this indicates that they cannot be removed by the drinking water production process. For this purpose, ultra-performance liquid chromatog. coupled with an ion-mobility high-resolution mass spectrometer (UPLC-IM-HRMS) was used in a combined approach including target, suspect and non-target screening anal. to identify known and unknown substances. Addnl., the role of ion-mobility-derived collision cross sections (CCS) in identification is discussed. To that end, six samples (two WWTP effluent samples, a surface water sample that received the effluents, a raw water sample from a downstream water reservoir, a process sample and the drinking water) were analyzed. Pos. findings for a total of 60 substances in at least one sample were obtained through quant. screening. Sixty-five percent (15 out of 23) of the identified substances in the drinking water sample were pharmaceuticals and transformation products of pharmaceuticals. Using suspect screening, further 33 substances were tentatively identified in one or more samples, where for 19 of these substances, CCS values could be compared with CCS values from the literature, which supported the tentative identification. Eight substances were identified by reference standards In the non-target screening, a total of ten features detected in all six samples were prioritized, whereby metoprolol acid/atenolol acid (a transformation product of the two β-blockers metoprolol and atenolol) and 1,3-benzothiazol-2-sulfonic acid (a transformation product of the vulcanization accelerator 2-mercaptobenzothiazole) were identified with reference standards Overall, this study demonstrates the added value of a comprehensive water monitoring approach based on UPLC-IM-HRMS anal. This study involved multiple reactions and reactants, such as 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0Computed Properties of C32H39NO4).

2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. Piperidine has a role as a reagent, a protic solvent, a base, a catalyst, a plant metabolite, a human metabolite and a non-polar solvent. Industrially, piperidine is produced by the hydrogenation of pyridine, usually over a molybdenum disulfide catalyst. Pyridine can also be reduced to piperidine via a modified Birch reduction using sodium in ethanol.Computed Properties of C32H39NO4

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

A study on prescription pattern of chronic kidney disease in tertiary care hospital was written by Saraswathi Pravallika, M.;Sampreethi, H.;Anusha, C. H.;Rohini, K.;Shete, Shivkumar. And the article was included in European Journal of Biomedical and Pharmaceutical Sciences in 2021.Electric Literature of C32H39NO4 The following contents are mentioned in the article:

The aim of the present investigation is to study the prescription pattern of chronic kidney disease in tertiary care hospital. The objective of the study was to study the prescription patterns of drugs used in chronic kidney disease and other comorbid conditions and to identify which drug is mostly prescribed at that hospital. To assess the rationality of prescription. To evaluate the medication adherence in CKD patients. The study on prescribing pattern definitely improves the quality of prescription writing, so study of drug prescribing pattern is relevant in the present scenario. To evaluate the prevalence of correct dosing in chronic kidney diseases depending on renal function estimation This is a retrospective, prospective observational study conducted over a period of six months. The study was conducted at Medicine ward of GLENEAGLES AWARE GLOBAL HOSPITAL LB.NAGAR. Patients who admitted to Nephrol. department of the hospital during a six- month period from Oct. 2021 to March 2021 are enrolled. CKD patients visiting the nephrologists are evaluated, diagnosed and prescribed with suitable therapy. All necessary details were collected from patient demographics, prescription chart, lab data, progress chart, medical records, doctor’s notes, nursing notes using a suitable designed data collection form. One hundred one patients were included in the project; with a mean age of 62.5. ± 18 years. More than half of patients were male, 77(76.2%). The mean BMI was 26 ± 1.15 kg/ m². The majority of patients were having normal weight 80 (79.2%), 15 (14.8%) patients had overweight, and obesity and only 6 (5.9%) patients were underweight. While 35 (34.6%) patients were smokers, 10 (9.9%) were ex-smokers and 56 (55.4%) patients were non- smokers. Anti- hypertensive agents are predominantly used among the patients. The most preferred options were beta blockers, calcium channel blockers and diuretics. Most of the physicians prescribed metoprolol (18.2%), amlodipine (38.3%), and cilnidipine (2%). Diuretics were the preferred option by the physician furosemide (92.3%), anti-platelets that are prescribed by the physicians are Aspirin (69.2%), clopidogrel (30.7%). Among the lipid lowering agents, atorvastatin (92.8%) was given to the most of the patients. sulbactam (20.4%), cefoperazone (20.4%), clarithromycin (10.25%), amoxycillin (10.25%) were mostly prescribed antibiotics in the study. The study concluded that most of the patients included in the study were suffering from chronic kidney disease. These may be due to their food habits, smoking, less exercise and poor health hygiene. The maximum number of patients was male; it may be due to smoking and alc. habits. Comorbidities such as hypertension, hyperglycemia, albuminuria, renal structure, and sex hormones, have been reported to have different effects on males and females. Thus, CKD progression may differ depending on sex. Early recognition with timely initiation of treatment in collaboration with nephrologists will improve the care for CKD patients. Thus, physicians and Nephrologists play an important outcome in patients with CKD. This study involved multiple reactions and reactants, such as 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0Electric Literature of C32H39NO4).

2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. Piperidine is a saturated organic heteromonocyclic parent, an azacycloalkane, a secondary amine and a member of piperidines. Fluorinated piperidines are also the subject of continued interest in medicinal chemistry, for example in the synthesis of selective dipeptidyl peptidase II (DPP II) inhibitors. Piperidine derivatives are also used in solid-phase peptide synthesis (SPPS) and many degradation reactions.Electric Literature of C32H39NO4

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

Evaluation of efficacy of Levocetrizine, Fexofenadine and their combination with monteleukast in allergic rhinitis in Jharkhand, India was written by Priyanki;Kumar, Pramveer;Kumari, Kusum;Ragini, Kavita;Chandra, Satish;Kumar, Sandeep;Gari, Manju. And the article was included in World Journal of Pharmacy and Pharmaceutical Sciences in 2021.Application In Synthesis of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid The following contents are mentioned in the article:

Allergic Rhinitis is the most common of all atopic diseases. It is an important public health problem. It affects 20-25% of world population. The most common pharmacol. treatment options include intranasal corticosteroids, antihistamines, Leukotriene (LT) pathway inhibitor, α-adrenergic agonist, etc. Here, we aim to compare the efficacy of Levocetrizine and Fexofenadine and also, to compare the efficacy of Levocetrizine + Montelukast and fexofenadine + Montelukast in the treatment of allergic rhinitis in a tertiary hospital in Jharkhand, India. This observational follow up study was conducted in the department of pharmacol. & Therapeutics, among the patient attending out patient department of Ear, Nose and Throat (ENT) of Rajendra Institute of Medical Sciences, Ranchi, Jharkhand with prior approval from Institutional ethics committee. Observational, single centered, randomised, open label, four arm, parallel-group, comparative clin. study. 110 Patients were enrolled who have met the inclusion criteria for the study from the OPD of ENT Department of RIMS during the study period. The patients were placed in four groups and received their resp. medication orally once daily in the evening for period of two weeks. On the day of the participant enrolment, a written informed consent was taken from all the patient, medical history, phys. examination, patient′s symptoms recorded on TNSS Sheet (Total Nasal Symptoms Score) and demonstrated to subject how to note and hand over the TNSS Sheet. After Completion of study on 15^th day, phys. examination and vital sign were checked; recording on sheet was collected. Mean changes in TNSS at the end of 24 h, 1^st and 2^nd week and comparison of effect of drugs with and without montelukast with the help of Total Nasal Score were calculated by using Statistical Package for the Social Sciences, IBM SPSS 20. The data was tabulated as mean ± standard deviation (Mean SD). Paired′t′ test was used to compare mean changes in TNSS Score before and after treatment. Out of total 110 enrolled patients, 98 completed the study, 4 patients not completed 2weeks treatment, 2 patients had change in disease pattern and 6 patient lost to follow up. The demog. characteristics of four groups were compared for age and sex. All groups had female predominance. The baseline Total Nasal Symtoms Score (TNSS) were comparable among the all four treatment groups. The mean TNSS was significantly reduced in all four study groups. After 1day of treatment change in TNSS have in following order Group C > Group D >Group A >Group B. Maximum change was observed in Levocetrizine & Montelukast combination group and min. change was observed in Fexofenadine group. Same order of change in TNSS was observed in study after 1 wk and 2weeks of treatment. So in our study Levocetrizine have been found better than fexofenadine in decreasing TNSS in allergic rhinitis patient. Similarly Levocetirizine-Montelukast combination decreases TNSS more than Fexofenadine-Montelukast combination. All the study drugs have shown significant improvement in quality of life of Allergic rhinitis patients. Levocetrizine has shown more effectiveness than Fexofenadine when used alone in allergic rhinitis patient. Levocetrizine-montelukast combination shows better effect than Fexofenadine-Montelukast combination drugs. This study involved multiple reactions and reactants, such as 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0Application In Synthesis of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid).

2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. Piperidine and its derivatives have become increasingly popular in many synthetic schemes. Piperidine derivatives bearing a masked aldehyde function in the ε-position are easily transformed into quinolizidine compounds through intramolecular reductive amination.Application In Synthesis of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

Acyl-lactone rearrangement. XXIII. Syntheses of cyclic amino acids by the reaction principle of the acyl-lactone rearrangement was written by Buechel, Karl Heinz;Korte, Friedhelm. And the article was included in Chemische Berichte in 1962.Name: Ethyl 2,3-dioxopiperidine-4-carboxylate The following contents are mentioned in the article:

3-Ethoxalyl-2-pyrrolidones and 3-ethoxalyl-2-piperidones were converted by heating with decarboxylation and rearrangement and by subsequent catalytic hydrogenation to DL-hygrinic acid (I), DL-proline (II), and DL-N-methylpipecolinic acid (III), resp., in high yields. N-Methyl-2-pyrrolidone and (CO₂Et)₂ (IV) were condensed with coarsely cut and with powd. K to yield 56 and 60-65%, resp., 3-ethoxalyl-N-methyl-2-pyrrolidone (V). V (1 g.) in 25 cc. concentrated HCl refluxed 20 hrs., concentrated in vacuo, diluted with 20 cc. H₂O, treated with 1 g. 2,4-(O₂N)₂C₆H₃NHNH₂ in 170 cc. 2N HCl, and kept several days gave the 2,4-dinitrophenylhydrazone of MeNH(CH₂)₃-COCO₂H, m. 183-4° (2N HCl). V (10 g.) in 60 cc. concentrated HCl refluxed 20 hrs. until the maximum at 285 mμ had disappeared, concentrated to 50 cc., cooled, filtered, from 0.1-0.3 g. V, diluted with H₂O, hydrogenated over 0.5 g. PtO₂, filtered, and evaporated, and the residual I.HCl (9 g.) dissolved in H₂O, passed through weakly basic Duolite A 7, and evaporated gave I, m. 174-5° (EtOH-Et₂O); I.HCl m. 183-5° (EtOH-Et₂O). 2-Pyrrolidone heated with excess Ac₂O gave 95% N-Ac derivative (VI), b₁₂ 109-10°. VI (127 g.) and 204 g. IV in 100 cc. dry Et₂O added dropwise at -5 to 0° to 39.1 g. powd. K and 1 cc. absolute EtOH in 400 cc. dry Et₂O, stirred 8 hrs., added with stirring and cooling to 500 cc. 2N HCl, and extracted with CHCl₃ gave 209 g. (crude) 3-ethoxalyl-N-acetyl-2-pyrrolidone (VII), b_0.05 90-5°, blue-violet with FeCl₃; the higher boiling fractions deposited 3-ethoxalyl-2-pyrrolidone, m. 134-6° (ligroine), blue with FeCl₃. Crude VII (5 g.) and 20 cc. 6N HCl heated 24 hrs. at 60° gave 1.2 g. 3-oxalyl-2-pyrrolidone, m. 208-10° (decomposition). VI (127 g.) and 180 g. IV added dropwise with stirring to 39.1 g. K and 1 cc. absolute EtOH in 400 cc. dry MePh at about 100° and worked up in the usual manner yielded 160 g. (crude) [EtO₂C(CH₂)₃NHCO]₂ (VIII), needles, m. 103-6° (ligroine, b. 80-110°). VIII refluxed with 6N HCl gave [HO₂C-(CH₂)₃NHCO]₂, m. 212°. The brown semisolid residue from the mother liquor from VIII treated in EtOH with C, concentrated, and diluted with petr. ether gave 26 g. 2,3-dioxo-4-carbethoxypiperidine, m. 148° (C₆H₆), ruby-red with FeCl₃. VII (22.7 g.) in concentrated HCl refluxed 1 hr., concentrated to half-volume, diluted with an equal volume H₂O, hydrogenated over 0.5 g. PtO₂, and worked up, and the residual crude II.HCl dissolved in H₂O, passed through Duolite A 7, eluted with 1.5 l. H₂O, and evaporated yielded 9 g. II, m. 214-15°. VII treated in the usual manner with 2,4-(O₂N)₂C₆H₃NH-NH₂ yielded the 2,4-dinitrophenylhydrazone of H₂N(CH₂)₃-COCO₂H, yellow, m. 217-18° (2N HCl). α-Ethoxalyl-N-methyl-2-piperidone (21.3 g.) added to 100 cc. boiling 6N HCl, refluxed about 5 min., concentrated to about 40 cc., diluted with an equal volume H₂O, hydrogenated over 0.5 g. PtO₂, and worked up yielded 17.9 g. III.HCl, m. 195-200°. III.HCl in H₂O treated with Amberlite 4-B and evaporated gave 14.0 g. III, m. 208-10° (EtOH-Et₂O). III treated in the usual manner with 2,4-(O₂N)₂C₆H₃-NHNH₂ gave the 2,4-dinitrophenylhydrazone of MeNH(CH₂)₄-COCO₂H, yellow needles, m. 207° (2N HCl). III (2.9 g.) in MeOH methylated with MeI-Ag₂O yielded DL-homostachydrine (IX), very hygroscopic crystals, m. 207-8° (EtOH-Et₂O); IX.-HCl, m. 211° (EtOH-Et₂O). This study involved multiple reactions and reactants, such as Ethyl 2,3-dioxopiperidine-4-carboxylate (cas: 30727-21-0Name: Ethyl 2,3-dioxopiperidine-4-carboxylate).

Ethyl 2,3-dioxopiperidine-4-carboxylate (cas: 30727-21-0) belongs to piperidine derivatives. Piperidine is a saturated organic heteromonocyclic parent, an azacycloalkane, a secondary amine and a member of piperidines. Piperidine derivatives bearing a masked aldehyde function in the ε-position are easily transformed into quinolizidine compounds through intramolecular reductive amination.Name: Ethyl 2,3-dioxopiperidine-4-carboxylate

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

Preparation of Δ¹-pyrroline-2-carboxylic acid and a new proline synthesis was written by Hasse, Kurt;Wieland, Alfred. And the article was included in Chemische Berichte in 1960.HPLC of Formula: 30727-21-0 The following contents are mentioned in the article:

2,3-Dioxopiperidine-4-carboxylic acid Et ester (I), obtained by condensation of 2-pyrrolidone (II) with (CO₂Et)₂ (III), was converted by hydrolysis to H₂N(CH₂)₃COCO₂H.HCl (IV) and this hydrogenated to yield DL-proline (V). K (10 g.) dissolved in 100 cc. absolute EtOH, the solution evaporated in vacuo, the residue dissolved in 200 cc. Et₂O, the solution treated with 25 cc. II and 50 cc. III in 50 cc. Et₂O, the mixture treated after 24 hrs. with 100 cc. 1:4 HCl, and the Et₂O phase concentrated gave 90% [EtO₂C(CH₂)₃NHCO]₂ (VI), m. 106° (H₂O or EtOH). VI (1 g.) in 5 cc. 6N HCl heated 1 hr. at 80° and concentrated gave [HO₂C(CH₂)₃NHCO]₂, m. 210°. II condensed in the usual manner with III, the mixture acidified with HCl, and the Et₂O phase evaporated in vacuo at 120° gave 3-ethoxalyl-2-pyrrolidone (VII), m. 132° (EtOH). 3-Oxalyl-2-pyrrolidone (VIII) (0.75 g.) and 20 cc. alc. HCl kept 36 hrs. at room temperature and evaporated in vacuo yielded VII, m. 131-2° (C₆H₆). VII (0.5 g.) in 5 cc. 6N HCl heated 0.5 hr. at 80° gave VIII, decomposing above 205°. K (4 g.) under 60 cc. Et₂O treated during 1 hr. with 13.8 g. absolute EtOH, warmed 3-4 hrs. on the water bath, treated at 0-5° with stirring with 14.6 g. III, the mixture treated after 10 min. during 0.5 hr. with 18.9 g. N-benzoyl-2-pyrrolidone in 27 cc. dry dioxane, diluted after 1 hr. with 150 cc. Et₂O, and filtered after 12 hrs., the residue dried in vacuo (23 g.), added with stirring to 40 cc. H₂O, 15 cc. HCl, and 30 cc. CHCl₃, the CHCl₃ phase evaporated, the residual oil dissolved at 90° with stirring during 10 min. in 40 cc. 6N HCl, and the hot solution filtered and cooled gave 2 g. VIII, needles, decomposing above 205° with sintering; the mother liquor gave 5.6 g. HO₂CCONH(CH₂)₃CO₂H, m. 163-4° (decomposition) (H₂O or Me₂CO). VIII (20.4 mg.) in 10 cc. H₂O treated with 15 cc. 1% 2,4-(O₂N)₂C₆H₃NHNH₂ in 2N HCl gave the 2,4-dinitrophenylhydrazone of VIII, m. 221° (decomposition). K (20 g.), a few crystals of iodine and a small amount of Hg₂Cl₂ in 50 cc. absolute C₆H₆ treated with 40 cc. absolute EtOH in portions, the mixture diluted with 30 cc. EtOH in 150 cc. C₆H₆, warmed slightly, diluted further with 300 cc. C₆H₆, treated with 43 g. II and 73 g. III, refluxed 18 hrs. with stirring, and treated with 80 cc. 6N HCl, the hot C₆H₆ layer decanted, the aqueous phase extracted with C₆H₆, and the combined C₆H₆ solutions worked up yielded 80% I, m. 148°. I (370 mg.) in EtOH hydrogenated at 20°/760 mm. over PtO₂, filtered, and evaporated gave 3-hydroxy-4-carbethoxy-2-piperidone, m. 121-2° (C₆H₆). I (5.3 g.) and 80 cc. 6N HCl refluxed 6 min. (in larger runs 20 min.) and evaporated at 35°/12 mm., and the residue refrigerated several hrs., filtered, washed with cold HCl, and dried yielded IV, m. 113° (HCl-AcOH-Et₂O). VIII (1.03 g.) and 35 cc. 6N HCl refluxed 1 hr. and evaporated at 35°/16 mm., the residue dissolved in H₂O and chromatographed on Dowex 50-X-8 (H form), and the fractions from 207-358 cc. evaporated gave 0.7 g. IV, m. 113° (decomposition). IV (48.7 mg.) hydrogenated 3 hrs. at 21°/755 mm. over PtO₂, filtered, treated with Ag₂O and then H₂S, refiltered, and evaporated, and the residue and 48 mg. picric acid dissolved in hot glacial AcOH and diluted with Et₂O gave the picrate of V, m. 134-5°. I (12.5 g.) and 200 cc. 6N HCl refluxed 7 min., concentrated at 40°/25 mm. to 30 cc., diluted with 120 cc. H₂O, hydrogenated 5 hrs. at 25°/1 atm. over 270 mg. PtO₂, filtered, placed on Amberlite IR-4B, washed with 1.3 l. H₂O, and eluted gave 5.51 g. pure V. This study involved multiple reactions and reactants, such as Ethyl 2,3-dioxopiperidine-4-carboxylate (cas: 30727-21-0HPLC of Formula: 30727-21-0).

Ethyl 2,3-dioxopiperidine-4-carboxylate (cas: 30727-21-0) belongs to piperidine derivatives.Piperidine is a key saturated heterocyclic scaffold found in several of the top-selling small molecule pharmaceuticals and natural alkaloids, with a diverse range of biological activities. Some chemotherapeutic agents have piperidine moiety within their structure, foremost among them, vinblastine and raloxifene.HPLC of Formula: 30727-21-0

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem